| Not Yet Recruiting | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma NCT07481721 | Ming Yang | Phase 1 |
| Active Not Recruiting | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas NCT07448480 | Blokhin's Russian Cancer Research Center | — |
| Recruiting | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas NCT06964737 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Terminated | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) NCT06193174 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208 | Nationwide Children's Hospital | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) NCT05540873 | CellabMED | Phase 1 |
| Active Not Recruiting | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma NCT05045027 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer NCT04521946 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children NCT04323046 | Sabine Mueller, MD, PhD | Phase 1 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma NCT04388475 | Oblato, Inc. | Phase 2 |
| Active Not Recruiting | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ R NCT04214392 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Fimepinostat in Treating Brain Tumors in Children and Young Adults NCT03893487 | Sabine Mueller, MD, PhD | EARLY_Phase 1 |
| Recruiting | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma NCT03896568 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors NCT03598244 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Completed | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma NCT01904123 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients Wit NCT02192359 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype NCT02658279 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma NCT02208362 | City of Hope Medical Center | Phase 1 |
| Unknown | Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients NCT01672463 | Oblato, Inc. | Phase 1 |
| Unknown | Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma NCT01144988 | Medical University Innsbruck | Phase 2 |
| Withdrawn | Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma NCT00378235 | INSYS Therapeutics Inc | Phase 1 / Phase 2 |